Nuowei praises: Intends to establish a joint venture with Yimiao Shen Zhou, holding a 50% stake.

Novimmune announced that the company recently signed a "Cell Therapy Cooperation Project Development Agreement" with E-medical China, planning to jointly establish a biopharmaceutical company with a registered capital of 40 million RMB, with each party holding 50% of the shares. The joint venture company will carry out investment cooperation projects in the field of cell therapy, aiming to empower the screening, prevention, and treatment of Alzheimer's disease with technological innovation throughout the entire prevention and treatment cycle. This investment does not need to be submitted to the company's board of directors or shareholders' meeting for approval, does not constitute a related party transaction or a major asset restructuring, and is expected to have no significant impact on the company's performance in 2025.